{"prompt": "['Protocol VX18-445-109, Version 1.0', 'Page 28 of 60', 'Subjects with new treatment-emergent ALT or AST elevations of >3 X ULN, with or without', 'total bilirubin >2 X ULN, must be followed closely, including confirmatory testing performed by', 'the central laboratory within 48 to 72 hours of the initial finding and subsequent close', 'monitoring of ALT, AST, and bilirubin levels, as clinically indicated.', 'If a subject cannot return to the site for central laboratory confirmatory testing, a local laboratory', 'may be used. Local laboratory results must be reported immediately to the medical monitor, and', 'the subject must have the tests repeated and sent to the central laboratory as soon as possible', '(ideally within 48 to 72 hours).', 'Study drug administration must be interrupted immediately (before confirmatory testing) if any', 'of the following criteria are met:', 'ALT or AST >8 X ULN', 'ALT or AST >5 X ULN for more than 2 weeks', 'ALT or AST >3 X ULN, in association with total bilirubin >2 X ULN and/or clinical jaundice', 'A thorough investigation of potential causes should be conducted, and the subject should be', 'followed closely for clinical progression.', 'Study drug administration must be discontinued if the following criterion is met:', 'Subsequent ALT or AST values confirm the initial elevation that satisfied the interruption', 'rule (above), and no convincing alternative etiology (e.g., acetaminophen use, viral hepatitis,', 'alcohol ingestion) is identified, regardless of whether transaminase levels have improved', 'All subjects in whom treatment is discontinued for elevated transaminases (and bilirubin, as', 'applicable) should have these levels monitored closely until levels normalize or return to', 'baseline.', 'If an alternative, reversible cause of transaminase elevation with or without increased bilirubin or', 'clinical jaundice has been identified, study drug administration may be resumed once', 'transaminases return to baseline or are 2 X ULN, whichever is higher. Regardless of the', 'duration of interruption, the medical monitor should be notified before resumption of study drug.', 'Upon resumption of study drug, transaminases and bilirubin should be assessed weekly for', '4 weeks. If a protocol-defined transaminase elevation interruption threshold recurs within', '4 weeks of rechallenge with the study drug (with confirmation of the initial elevation by repeat', 'testing within 48 to 72 hours), then the study drug must be permanently discontinued, regardless', 'of the presumed etiology.', '9.8.2', 'Rash', 'Individuals who develop a generalized rash will be monitored closely. Study drug dosing should', 'be interrupted if a subject develops a generalized rash of Grade 3 or higher, or a rash that is', 'considered a serious adverse event (SAE). The investigator will notify the medical monitor of', 'any rash that results in interruption of study drug, is Grade 3 or higher (Section 13.1.1.4), or is an', 'SAE. Investigators should consider additional evaluation including laboratory testing (e.g.,', 'complete blood count with differential, liver function tests), photographs of the rash, and', 'dermatology consultation. The investigator may consider resumption of study drug if considered', 'clinically appropriate.', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 29 of 60', '9.9', 'Removal of Subjects', 'Subjects may withdraw from the study at any time at their own request. Subjects may be', 'withdrawn from study drug treatment at any time at the discretion of the investigator or Vertex', 'for safety, behavior, noncompliance with study procedures, or administrative reasons. If a subject', 'has been withdrawn from study drug treatment, the subject will continue to be followed,', 'provided that the subject has not withdrawn consent (and assent, as applicable).', 'In addition, a subject must be discontinued from study drug treatment if the subject meets any of', 'the following criteria:', 'Has a screening CFTR genotype that does not confirm study eligibility if a previous CFTR', 'genotype laboratory report was used to establish eligibility. These subjects must be', 'discontinued from the study (Section 8.1)', 'Meets any of the stopping (discontinuation) criteria (Section 9.8)', 'Becomes pregnant (Section 11.5.7.2)', 'Subjects who discontinue study drug treatment should return for study assessments, as noted in', 'Section 9.1.5.2.', 'If a subject does not return for a scheduled visit, reasonable effort will be made to contact the', 'subject. In any circumstance, reasonable effort will be made to document subject outcome. The', 'investigator will inquire about the reason for withdrawal, request that the subject return all', 'unused investigational product(s), request that the subject return for an ETT Visit and Safety', 'Follow-up Visit, if applicable (see Section 9.1.5), and follow up with the subject regarding any', 'unresolved AEs.', 'If the subject withdraws consent or assent for the study, no further assessments will be', 'performed. Vertex may retain and continue using the study data and samples after the study is', 'over, and may use the samples and information in the development of the study compound, and', 'for other drugs and diagnostics, in publications and presentations, and for education purposes. If', 'the subject withdraws from the study, the study data and samples collected will remain part of', 'the study. A subject will not be able to request the withdrawal of his/her information from the', 'study data. A subject may request destruction of the samples collected from him/her during the', 'study as long as those samples can be identified as his/her samples.', '9.10', 'Replacement of Subjects', 'Subjects who withdraw or are withdrawn before the first dose of randomized study drug on', 'Day 1 of the Treatment Period may be replaced.', 'Subjects who withdraw or are withdrawn for nonsafety reasons during the study drug treatment', \"periods may be replaced at Vertex's discretion.\", '10', 'STUDY DRUG INFORMATION AND MANAGEMENT', 'During the TEZ/IVA Run-in Period, study drug refers to TEZ/IVA and IVA.', 'During the Treatment Period, study drug refers to VX-445/TEZ/IVA and matching placebo,', 'TEZ/IVA and matching placebo, and IVA.', 'Vertex Pharmaceuticals Incorporated']\n\n###\n\n", "completion": "END"}